Arena Pharmaceuticals (ARNA): Q2 EPS loss of -$0.12 misses by $0.04. Revenue of $22M (+566% Y/Y)...

This news story has 5 comments:

Register or Login to rate comments »

TOAN VINH TRAN Comment (1)
 
I am thinking, higher revenue and higher loss.
10 Aug 2012, 12:27 AM Reply Like

MexCom Comments (2834)
 
Welcome to SA. I see that this is your first comment. Please provide a bio for us to evaluate better what you are saying. Your implication that they will lose money on their new product needs some more elaboration. Why do you feel that way?

BTW - what attracted you here? Have you only been a reader?
10 Aug 2012, 06:07 AM Reply Like

plhovsepian Comments (6)
 
These guys haven't even started to sell their main product. Besides, the drug by itself is only one of many tools in obesity weight reduction. There needs to be counseling, goals and as exercise program.
I think a great business plan would be weight loss centers that use doctors and counselors to help to support people to wean themselves off the compulsion to eat. This, like alcohol addiction, is a life long program and bleviq can play an important role. BUT it is just one of many tools.

Paul

Paul
10 Aug 2012, 12:59 AM Reply Like

New Superhuman Comments (840)
 
These numbers are meaningless, as any smart investor in ARNA knows.

Last call before this train leaves the station. It's not coming back.
10 Aug 2012, 05:52 AM Reply Like

MexCom Comments (2834)
 
Along with VVUS's new product we can look forward to better weight reduction therapies and improved health of the population. Investors should take pride in helping provide the capital needed for this enterprise.
10 Aug 2012, 06:11 AM Reply Like